Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dicitrinone G is a rare carbon-bridged citrinin dimer isolated from the marine-derived fungus *Penicillium sp.* GGF 16-1-2, which was originally found in symbiotic association with a starfish. As a small molecule research compound, it has demonstrated significant anti-pancreatic cancer activity and potent antifungal properties. Its mechanism of action in oncology involves the inhibition of pancreatic angiogenesis through the regulation of the NLRP3 inflammasome and the IL-18 pathway. Furthermore, dicitrinone G has been shown to induce apoptosis in human pancreatic cancer cell lines, such as BXPC-3 and PANC-1, by activating caspase-3. In addition to its cytotoxic effects, the compound exhibits strong antifungal activity against pathogens like *Colletotrichum gloeosporioides*.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dicitrinone G.